New treatment for pancreatic cancer: a revolution?
Daraxonrasib, an experimental drug, has shown promising results in treating pancreatic cancer, doubling patients' life expectancy. Presented at the ASCO conference, this treatment has sparked rare hope in the medical community.
New treatment for pancreatic cancer: a revolution?
May 31, 2026
Pancreatic cancer, one of the most aggressive and difficult to treat, could see a decisive turning point. An experimental drug, daraxonrasib, has just demonstrated unprecedented results in clinical trials. Patients with this disease see their life expectancy double compared to current treatments.
This advance, presented on Sunday at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, has sparked rare hope in the medical community. Daraxonrasib, developed by the biotechnology company Revolution Medicines, specifically targets the molecular mechanisms of the tumor.
Unprecedented clinical results
The study data, published simultaneously in the New England Journal of Medicine, reveal a spectacular improvement. Patients treated with daraxonrasib survived on average twice as long as those receiving standard chemotherapy. This gain represents a first in the treatment of this cancer, often diagnosed at an advanced stage.
The drug also reduces the risk of death by 60% compared to chemotherapy. These figures, obtained from a sample of several hundred patients, confirm its therapeutic potential. Side effects, although present, remain manageable and comparable to those of existing treatments.
Enthusiastic reactions from specialists
The announcement sent shockwaves through oncologists. Rachna Shroff, a pancreatic cancer expert at the University of Arizona, described these results as "incredibly impactful." She admitted to being moved to tears upon discovering the data, emphasizing that nothing comparable had been observed before.
Other doctors hailed a major advance while calling for caution. Daraxonrasib does not cure the disease, but it offers significant respite to patients. Its mechanism of action, targeting a genetic mutation frequent in pancreatic tumors, paves the way for more precise treatments.
An innovative mechanism of action
Unlike traditional chemotherapies, which indiscriminately attack cancerous and healthy cells, daraxonrasib acts on a specific molecular pathway. It blocks a protein involved in tumor growth, thus limiting the progression of the disease.
This approach, known as precision medicine, reduces adverse effects while increasing the effectiveness of the treatment. Trials have shown that the drug was particularly effective in patients with the KRAS mutation, present in nearly 90% of pancreatic cancers.
Next steps and challenges to overcome
Despite these promising results, daraxonrasib is not yet available to patients. Revolution Medicines plans to launch additional clinical trials to confirm its efficacy and safety. An authorization request could be submitted to health authorities within two years.
The cost of the treatment also remains a pending question. Targeted therapies, often expensive, raise debates about their accessibility. Health systems will need to evaluate their cost-benefit ratio before any potential coverage.
Conclusion: a hope to be realized
Daraxonrasib marks a crucial step in the fight against pancreatic cancer. Its results, although preliminary, offer a glimmer of hope to thousands of patients. If the next trials confirm its efficacy, this drug could transform the management of this devastating disease.
Researchers remain cautious, however. Further studies will be needed to refine the protocols and identify the patients most likely to benefit from this treatment. In the meantime, the medical community welcomes an advance that could redefine therapeutic standards.
Key Points
- Daraxonrasib doubles the life expectancy of patients with pancreatic cancer.
- The drug specifically targets the molecular mechanisms of the tumor.
- The results were presented at the annual ASCO conference.
- The treatment reduces the risk of death by 60% compared to chemotherapy.
- Daraxonrasib is not yet available and requires additional clinical trials.
Sources
- NPR Top Stories - "Experimental pill promises new hope for deadly pancreatic cancer". (secondary)
- France Info Santé - ""It's a revolution": why daraxonrasib, a new treatment against pancreatic cancer, raises high hopes". (secondary)
- STAT News - "STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug". (secondary)
- Straits Times SG - "Experimental pancreatic cancer pill doubles survival chances, boosts quality of life". (secondary)
Transparency: 4 sources (0 primary, 4 secondary). Verification: May 31, 2026.
Truthyx - May 31, 2026